Should I buy or sell Revolution Medicines stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks .

What is Revolution Medicines' stock price target for 2024?

8 Wall Street research analysts have issued twelve-month target prices for Revolution Medicines' shares. Their RVMD share price targets range from $23.00 to $47.00. On average, they expect the company's share price to reach $35.50 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts .

How have RVMD shares performed in 2023?

Revolution Medicines' stock was trading at $23.82 at the beginning of 2023. Since then, RVMD stock has increased by 2.6% and is now trading at $24.45. View the best growth stocks for 2023 here .

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our RVMD earnings forecast .

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) issued its earnings results on Monday, November, 6th. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.02. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.92%. During the same period in the prior year, the company earned ($0.87) EPS.

What ETFs hold Revolution Medicines' stock?

ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) , SPDR S&P Biotech ETF (XBI) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC) . Invesco Nasdaq Biotechnology ETF (IBBQ) .

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC) , Editas Medicine (EDIT) , Homology Medicines (FIXX) , Gossamer Bio (GOSS) , Livongo Health (LVGO) , Sorrento Therapeutics (SRNE) , Black Diamond Therapeutics (BDTX) , Beam Therapeutics (BEAM) , CrowdStrike (CRWD) and Precision BioSciences (DTIL) .

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.65%), Column Group LLC (1.12%), Ameriprise Financial Inc. (1.11%), Northern Trust Corp (0.85%), Morgan Stanley (0.73%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Anthony W Boor, Barbara Weber , Jack Anders , Jeanna Steele, Jeff Cislini , Lorence H Kim , Margaret A Horn , Mark A Goldsmith, Mark A Goldsmith , Peter Svennilson , Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey , Thilo Schroeder , Vincent A Miller and Xiaolin Wang . View institutional ownership trends .

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Revolution Medicines Stock Price, News & Analysis (NASDAQ:RVMD)

$24.70

+0.73 (+3.05%)

(As of 02:51 PM ET)

Compare

Today's Range: $23.82
▼
$24.82
50-Day Range: $18.35
▼
$34.12
52-Week Range: $15.44
▼
$35.60

Volume: 776,799 shs
Average Volume: 1.47 million shs
Market Capitalization: $2.71 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.50

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 45.2% Upside
$35.50 Price Target
Short Interest: Bearish
14.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Selling Shares
$1.81 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.48) to ($3.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

372nd out of 958 stocks

Biotechnology Industry

24th out of 75 stocks

4.4

Analyst's Opinion

Consensus Rating
Revolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.50, Revolution Medicines has a forecasted upside of 45.2% from its current price of $24.45.
Amount of Analyst Coverage
Revolution Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
14.83% of the outstanding shares of Revolution Medicines have been sold short.
Short Interest Ratio / Days to Cover
Revolution Medicines has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Revolution Medicines has recently increased by 14.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Revolution Medicines does not currently pay a dividend.
Dividend Growth
Revolution Medicines does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revolution Medicines is -0.81.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Revolution Medicines this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,178.00 in company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Revolution Medicines is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Revolution Medicines are expected to grow in the coming year, from ($3.48) to ($3.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revolution Medicines is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revolution Medicines is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revolution Medicines has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVMD Stock News Headlines

December 1, 2023 | americanbankingnews.com

Head-To-Head Survey: Revolution Medicines (NASDAQ:RVMD) & Clarus Therapeutics (OTCMKTS:CRXTQ)

November 29, 2023 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by Brokerages

December 7, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.

November 24, 2023 | benzinga.com

Revolution Medicines Stock (NASDAQ:RVMD) Dividends: History, Yield and Dates

November 17, 2023 | finance.yahoo.com

A great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who own 74% must be happy

November 16, 2023 | msn.com

Raymond James starts coverage of Revolution Medicines at outperform

November 16, 2023 | markets.businessinsider.com

Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details

November 10, 2023 | seekingalpha.com

Revolution Medicines: A March Halted By 'Lackluster' ESMO Readout

December 7, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

November 8, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Myriad Genetics (MYGN), Revolution Medicines (RVMD) and Demant (OtherWILLF)

November 8, 2023 | finance.yahoo.com

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

November 7, 2023 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About Revolution Medicines

November 7, 2023 | finance.yahoo.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript

November 6, 2023 | seekingalpha.com

Revolution Medicines, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 6, 2023 | seekingalpha.com

Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcript

November 6, 2023 | finance.yahoo.com

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

November 6, 2023 | finance.yahoo.com

Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress

November 1, 2023 | finance.yahoo.com

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

October 31, 2023 | finance.yahoo.com

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

October 26, 2023 | markets.businessinsider.com

Promising Phase 1 Results and Future Potential Drive Buy Rating for Revolution Medicines

October 26, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Revolution Medicines (RVMD)

October 25, 2023 | markets.businessinsider.com

Revolution Medicines Earns Buy Rating Based on Promising Phase I Data and Strong RAS Pathway Development Prospects

October 24, 2023 | msn.com

Oppenheimer Maintains Revolution Medicines (RVMD) Outperform Recommendation

October 23, 2023 | finance.yahoo.com

Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers

October 23, 2023 | finance.yahoo.com

Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.

October 23, 2023 | benzinga.com

Revolution Medicines Stock (NASDAQ:RVMD), Analyst Ratings, Price Targets, Predictions

October 23, 2023 | finance.yahoo.com

Revolution Crashes 43% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.

See More Headlines

Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVMD
CUSIP: N/A
CIK: 1628171
Web: www.revmed.com
Phone: 650-481-6801
Fax: N/A
Employees: 338
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.50
High Stock Price Target: $47.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +48.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-248,710,000.00
Net Margins: -1,003.36%
Pretax Margin: -1,281.44%
Return on Equity: -38.92%
Return on Assets: -33.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.64
Quick Ratio: 9.64

Sales & Book Value

Annual Sales: $35.38 million
Price / Sales: 74.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.72 per share
Price / Book: 3.10

Miscellaneous

Outstanding Shares: 109,570,000
Free Float: 100,252,000
Market Cap: $2.63 billion
Optionable: Not Optionable
Beta: 1.50

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Mark A. Goldsmith Ph.D. (Age 61)
CEO, President & Chairman
Comp: $1.05M
Mr. Jack Anders (Age 46)
Chief Financial Officer
Comp: $544.8k
Ms. Margaret A. Horn J.D. (Age 60)
Chief Operating Officer
Comp: $775.6k
Dr. Stephen M. Kelsey FRC Path. (Age 62)
FRCP, M.D., President of Research & Development
Comp: $779k
Ms. Xiaolin Wang (Age 52)
Executive Vice President of Clinical Development
Comp: $604.1k
Dr. Martin D. Burke M.D.
Ph.D., Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D. (Age 42)
Academic Co-Founder & Member of Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D.
Academic Co-Founder & Member of Scientific Advisory Board
Mr. Walter Reiher Ph.D.
Chief Information Officer
Ms. Jan Smith Ph.D.
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.
What is Revolution Medicines' stock price target for 2024?: 8 Wall Street research analysts have issued twelve-month target prices for Revolution Medicines' shares. Their RVMD share price targets range from $23.00 to $47.00. On average, they expect the company's share price to reach $35.50 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.
How have RVMD shares performed in 2023?: Revolution Medicines' stock was trading at $23.82 at the beginning of 2023. Since then, RVMD stock has increased by 2.6% and is now trading at $24.45.
View the best growth stocks for 2023 here.
When is Revolution Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our RVMD earnings forecast.
How were Revolution Medicines' earnings last quarter?: Revolution Medicines, Inc. (NASDAQ:RVMD) issued its earnings results on Monday, November, 6th. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.02. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.92%. During the same period in the prior year, the company earned ($0.87) EPS.
What ETFs hold Revolution Medicines' stock?: ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Revolution Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).
When did Revolution Medicines IPO?: (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.
Who are Revolution Medicines' major shareholders?: Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.65%), Column Group LLC (1.12%), Ameriprise Financial Inc. (1.11%), Northern Trust Corp (0.85%), Morgan Stanley (0.73%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends.
How do I buy shares of Revolution Medicines?: Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Revolution Medicines Stock Price, News & Analysis (NASDAQ:RVMD)

Revolution Medicines MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Revolution Medicines Stock (NASDAQ:RVMD)

RVMD Stock Price History

RVMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RVMD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™